Defining Factors That Allow for a More Personalized Approach to Stage I NSCLC [0.03%]
早期非小细胞肺癌更个性化治疗的影响因素分析
Jessica S Donington
Jessica S Donington
Comparing Survival in Patients With Lung Cancer With and Without a History of Common Autoimmune Disease [0.03%]
自身免疫性疾病的病史对肺癌患者生存期的影响及其作用机制
Demitrios Dedousis,Anastasia N Vassiliou,Shufen Cao et al.
Demitrios Dedousis et al.
Introduction: Autoimmune disease has both a predisposing and a protective effect toward malignancy. Though studies have investigated the risk of malignancy in patients with autoimmune disease, there is limited research on...
Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report [0.03%]
克唑替尼耐药的ROS1 G2101A突变对lorlatinib敏感：案例报告
Parvin Begum,Wanyuan Cui,Sanjay Popat
Parvin Begum
gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an a...
Immunochemotherapy Disrupts Peripherally Located Lung Squamous Cell Carcinoma Resulting in Pleuritis: A Report of Two Cases, Case Report [0.03%]
免疫化疗破坏外周型肺鳞状细胞癌导致胸膜炎：两例报告
Kei Kunimasa,Tomohiro Maniwa,Motohiro Tamiya et al.
Kei Kunimasa et al.
Immunochemotherapy is widely used as the primary treatment for advanced lung cancer and is currently being investigated in the perioperative setting. Immunochemotherapy can produce marked tumor shrinkage and long-term anticancer effects tha...
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC [0.03%]
广泛期小细胞肺癌中，肿瘤免疫微环境和 frameshift 新抗原负荷决定PD-L1阻断的反应
Hiroaki Kanemura,Hidetoshi Hayashi,Shuta Tomida et al.
Hiroaki Kanemura et al.
Introduction: Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small...
Association Between EGFR and ALK Mutation Status on Patient-Reported Symptoms After Palliative Radiation for Bone Pain in NSCLC [0.03%]
EGFR和ALK突变状态与接受姑息放射治疗的非小细胞肺癌骨痛患者的症状之间的相关性
Daegan Sit,Michelle Bale,Vincent Lapointe et al.
Daegan Sit et al.
Introduction: After palliative radiotherapy for bone metastases from NSCLC, up to 30% of patients may derive no symptomatic benefit, and there are a lack of biological predictors for this. The purpose was to investigate w...
Kristin M Primm,Hui Zhao,Daphne C Hernandez et al.
Kristin M Primm et al.
Introduction: Detailed evaluations of racial and ethnic trends and disparities in NSCLC outcomes are lacking, and it remains unclear whether recent advances in screening and targeted therapies for NSCLC have benefited all...
Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Sta ge NSCLC With High Programmed Death-Ligand 1 Express ion [0.03%]
简报：一种基于血液的微小核糖核酸互补诊断可预测PD-L1高表达晚期NSCLC患者免疫治疗疗效
Timothy Rajakumar,Rastislav Horos,Paul Kittner et al.
Timothy Rajakumar et al.
Introduction: Patients with advanced, non-oncogene-driven NSCLC with high programmed death-ligand 1 (PD-L1) expression are eligible for treatment with immunotherapy. There is, however, an urgent medical need for biomarker...
Chan Yeu Pu,Christine M Lusk,Christine Neslund-Dudas et al.
Chan Yeu Pu et al.
Introduction: Lung cancer screening criteria should select candidates with minimal cardiopulmonary comorbidities who are fit for curative lung cancer resection. ...
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC [0.03%]
Ⅰb期研究： Alecensa与T药联合治疗ALK阳性晚期NSCLC的安全性和抗肿瘤活性的短期报告
Dong-Wan Kim,Shirish Gadgeel,Scott N Gettinger et al.
Dong-Wan Kim et al.
Introduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. ...